Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.

about

Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.

Item

http://www.wikidata.org/entity/Q38681598

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Etoposide and doxorubicin enha ...... modulation of TRAIL-DR5 axis.

@en

type

Item

label

Etoposide and doxorubicin enha ...... modulation of TRAIL-DR5 axis.

@en

prefLabel

Etoposide and doxorubicin enha ...... modulation of TRAIL-DR5 axis.

@en

P1476

Etoposide and doxorubicin enha ...... modulation of TRAIL-DR5 axis.

@en

P2093

Anmada Nayak

http://www.w3.org/2001/XMLSchema#string

Chanakya Nath Kundu

http://www.w3.org/2001/XMLSchema#string

Chinmayee Sethy

http://www.w3.org/2001/XMLSchema#string

Deepika Nayak

http://www.w3.org/2001/XMLSchema#string

Neha Tripathi

http://www.w3.org/2001/XMLSchema#string

Prasad V Bharatam

http://www.w3.org/2001/XMLSchema#string

Sarita Das

http://www.w3.org/2001/XMLSchema#string

Sumit Siddharth

http://www.w3.org/2001/XMLSchema#string

P2860

Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

Targeting the Checkpoint to Kill Cancer Cells

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

Systemic treatment strategies for triple-negative breast cancer.

VMD: visual molecular dynamics

The anti-cancer activities of Vernonia amygdalina extract in human breast cancer cell lines are mediated through caspase-dependent and p53-independent pathways

Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.

P2888

s10495-017-1400-4

P31

scholarly article

P356

10.1007/S10495-017-1400-4

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28702823

http://www.w3.org/2001/XMLSchema#string